BiotechTube

RP-L401

Phase 1Terminated
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infantile Malignant Osteopetrosis

Conditions

Infantile Malignant Osteopetrosis

Trial Timeline

Nov 19, 2020 → May 21, 2021

NCT ID
NCT04525352

About RP-L401

RP-L401 is a phase 1 stage product being developed by Rocket Pharmaceuticals for Infantile Malignant Osteopetrosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04525352. Target conditions include Infantile Malignant Osteopetrosis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04525352Phase 1Terminated

Competing Products

16 competing products in Infantile Malignant Osteopetrosis

See all competitors
ProductCompanyStageHype Score
TSHA-101Taysha Gene TherapiesPhase 1/2
36
MAS825 + PlaceboNovartisPhase 2
52
alglucosidase alfa + alglucosidase alfaSanofiApproved
84
MyozymeSanofiPhase 2
51
Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
84
RadiprodilUCBPhase 2
49
Larotrectinib (Vitrakvi, BAY2757556) + Standard of CareBayerPre-clinical
20
Sabril®LundbeckPre-clinical
20
VigabatrinLundbeckApproved
82
NusinersenBiogenPre-clinical
20
GWP42003-PJazz PharmaceuticalsPhase 3
74
GWP42003-PJazz PharmaceuticalsPhase 3
74
Cerliponase AlfaBioMarin PharmaceuticalPre-clinical
20
Cholic AcidsMirum PharmaceuticalsPhase 3
74
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
74
ATB200 + AT2221Amicus TherapeuticsPre-clinical
20

Other Products from Rocket Pharmaceuticals

RP-L102Phase 2
44
RP-L102Phase 2
44
RP-L301Phase 2
44
RP-L201Phase 1/2
33
RP-L201Phase 1
25